Search
Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study
Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.
Read moreInternational Survey of T2* Cardiovascular Magnetic Resonance in Thalassemia
Thalassemia major (TM) is a substantial health issue, with over 25,000 new transfusion- dependent children identified each year around the world.
Read moreEHA reaffirms commitment to hematology's future with new brand identity
The European Hematology Association (EHA) is thrilled to announce the launch of our new brand identity. This includes a refreshed logo, updated color palette, and a new slogan, marking a significant milestone in our journey.
Read more1st European EHA Sickle Cell Conference
EHA is teaming up with the Annual Scientific Conference on Sickle Cell and Thalassaemia, 2020 and the British Society of Haematology (BSH) to co-organize this first European Sickle Cell Conference; and also as a result of COVID-19 offer it as…
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- »